Ashish Gautam's Biography

Ashish Gautam, Global Brand Medical Head - ADCETRIS, Takeda Oncology

Dr. Ashish Gautam, PhD, MBA is Global Brand Medical Head in the Global Medical Affairs division of Takeda Oncology based in Cambridge, Massachusetts, USA. His research interests have been in advancing the understanding of oncologic pathways and clinical development of cancer drugs. He has published in several peer reviewed oncology focused journals. Dr. Gautam started working on lung cancer at Duke University with a focus on identifying tumor suppressor genes and later continued the research at Roswell Park cancer Institute in Buffalo, NY and then at Moffitt Cancer Center in Tampa Florida. His work on RRM1 and ERCC1 and the first clinical trial in front line NSCLC on doublet chemotherapy choice based on the expression levels of these 2 genes has been published and led to a large phase III SWOG study. Dr. Gautam joined AstraZeneca Medical Affairs in 2005 to work on new TKIs in lung and thyroid cancers and was involved in the approval of Caprelsa in medullary thyroid cancer. In 2012, Dr. Gautam joined Takeda Oncology as the Global Medical Lead for ADCETRIS that received approval for the treatment of relapsed or refractory Hodgkin Lymphoma post ASCT ; after 2 chemotherapies for ASCT ineligible patients and systemic Anaplastic Large Cell Lymphoma by FDA in 2011 and by EMEA in 2012. In 2016, ADCETRIS was approved as post-ASCT consolidation for patients at increased risk of relapse or progression following ASCT. Dr. Gautam continues to support all Global Medical Affairs activities in his current role as Global Brand Medical Head to ensure ADCETRIS is developed and becomes available for the patients that require this important treatment.